Amgen (AMGN.O), and AstraZeneca (AZN.L), said on Tuesday their asthma drug helped reduce swallowing difficulties and achieved disease remission in 69% of patients with a type of chronic inflammatory disorder of the esophagus. The result builds on August data, when AstraZeneca said the drug met the trial's main goals after 24 weeks of treatment by reducing esophageal inflammation and easing swallowing difficulties versus placebo.
Read more
